Anavex Life Sciences Corp. (NASDAQ:AVXL) was down 2.8% during mid-day trading on Tuesday . The stock traded as low as $7.09 and last traded at $7.25, with a volume of 610,922 shares traded. The stock had previously closed at $7.46.

Several equities research analysts have recently issued reports on AVXL shares. Maxim Group reaffirmed a “buy” rating and issued a $15.00 target price on shares of Anavex Life Sciences Corp. in a report on Wednesday, June 22nd. Zacks Investment Research cut Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Finally, FBR & Co reissued an “outperform” rating and set a $10.00 price objective on shares of Anavex Life Sciences Corp. in a research note on Tuesday.

The firm has a 50 day moving average of $5.63 and a 200 day moving average of $4.87. The company’s market cap is $267.47 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its quarterly earnings data on Wednesday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.10. Equities analysts predict that Anavex Life Sciences Corp. will post ($0.34) EPS for the current fiscal year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.